CCCC Stock Analysis: Buy, Sell, or Hold?
CCCC - C4 Therapeutics, Inc.
$2.70
0.07 (2.66%)
▲
5d:
+0.37%
30d:
-8.47%
90d:
+37.76%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
CCCC is down 11.5% this week, but smart money is accumulating calls. Top strike: $3 2026-04-17 with 1,624 OI. Call ratio: 67% View Scanner →
Strength: 7.4/10
Get Alerted When CCCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CCCC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CCCC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CCCC is currently trading at $2.70, which is considered fair relative to its 30-day fair value range of $2.48 to $3.04.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $2.30, while resistance sits at $2.85.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.57 (+328.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $2.30, while resistance sits at $2.85.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.57 (+328.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$2.48 -
$3.04
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 328.6% below Wall St target ($11.57)
Fair Price Analysis
30-Day Fair Range
$2.48 -
$3.04
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$2.30
Resistance Level
$2.85
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.20
Wall Street Target
$11.57
(+328.6%)
Revenue Growth (YoY)
112.8%
Profit Margin
-292.1%
Share & Embed Analysis
Last updated: April 02, 2026 9:07 AM ET
Data refreshes hourly during market hours. Next update: 10:07 AM
Data refreshes hourly during market hours. Next update: 10:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CCCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Leonard Reyno
SELL
10000 shares
2026-01-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 45 HOLD |
